By Drug Target Review2024-05-30T12:00:34
Researchers discovered that HER2-positive breast cancer drugs must target both HER2 and EGFR receptors to eradicate disease.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2023-01-16T10:21:42
Sponsored by Sartorius Incucyte® Live-Cell Analysis System
2023-02-23T14:02:18
Sponsored by bit.bio
2023-03-08T16:29:20
Sponsored by Bio-Techne
2023-03-07T10:55:58
Sponsored by Agilent
2023-01-19T15:38:17
Sponsored by Cell Signaling Technology
Site powered by Webvision Cloud